{"id":"https://openalex.org/W3180220992","doi":"https://doi.org/10.1158/1538-7445.am2021-891","title":"Abstract 891: Cost-effectiveness of CDK4/6 inhibitors in the first-line treatment of HR+/HER2- metastatic breast cancer in postmenopausal women in the United States","display_name":"Abstract 891: Cost-effectiveness of CDK4/6 inhibitors in the first-line treatment of HR+/HER2- metastatic breast cancer in postmenopausal women in the United States","publication_year":2021,"publication_date":"2021-07-01","ids":{"openalex":"https://openalex.org/W3180220992","doi":"https://doi.org/10.1158/1538-7445.am2021-891","mag":"3180220992"},"language":"en","primary_location":{"id":"doi:10.1158/1538-7445.am2021-891","doi":"https://doi.org/10.1158/1538-7445.am2021-891","is_oa":false,"landing_page_url":"https://doi.org/10.1158/1538-7445.am2021-891","pdf_url":null,"source":{"id":"https://openalex.org/S168522863","display_name":"Cancer Research","issn_l":"0008-5472","issn":["0008-5472","1538-7445"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320273","host_organization_name":"American Association for Cancer Research","host_organization_lineage":["https://openalex.org/P4310320273"],"host_organization_lineage_names":["American Association for Cancer Research"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Cancer Research","raw_type":"journal-article"},"volume":null,"type":"conference-abstract","indexed_in":["crossref"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5054921613","display_name":"Prajakta P. Masurkar","orcid":"https://orcid.org/0000-0002-1417-9764","observed_orcids":["https://orcid.org/0000-0002-1417-9764"]},"institutions":[{"id":"https://openalex.org/I44461941","display_name":"University of Houston","ror":"https://ror.org/048sx0r50","country_code":"US","type":"education","lineage":["https://openalex.org/I44461941"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Prajakta P. Masurkar","raw_affiliation_strings":["1University of Houston, Houston, TX;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1University of Houston, Houston, TX;","institution_ids":["https://openalex.org/I44461941"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5001113735","display_name":"Haluk Damgacioglu","orcid":"https://orcid.org/0000-0003-4361-4515","observed_orcids":["https://orcid.org/0000-0003-4361-4515"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Haluk Damgacioglu","raw_affiliation_strings":["2University of Texas, Houston, TX"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"2University of Texas, Houston, TX","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5001892869","display_name":"Ashish A. Deshmukh","orcid":"https://orcid.org/0000-0001-8936-8108","observed_orcids":["https://orcid.org/0000-0001-8936-8108"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Ashish Deshmukh","raw_affiliation_strings":["2University of Texas, Houston, TX"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"2University of Texas, Houston, TX","institution_ids":[]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5044880752","display_name":"Meghana V. Trivedi","orcid":"https://orcid.org/0000-0002-0585-5580","observed_orcids":["https://orcid.org/0000-0002-0585-5580"]},"institutions":[{"id":"https://openalex.org/I44461941","display_name":"University of Houston","ror":"https://ror.org/048sx0r50","country_code":"US","type":"education","lineage":["https://openalex.org/I44461941"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Meghana Trivedi","raw_affiliation_strings":["1University of Houston, Houston, TX;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1University of Houston, Houston, TX;","institution_ids":["https://openalex.org/I44461941"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":1,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":null,"has_fulltext":false,"cited_by_count":3,"citation_normalized_percentile":null,"cited_by_percentile_year":null,"biblio":{"volume":"81","issue":"13_Supplement","first_page":"891","last_page":"891"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T12829","display_name":"Advanced Breast Cancer Therapies","score":0.8065999746322632,"subfield":{"id":"https://openalex.org/subfields/2740","display_name":"Pulmonary and Respiratory Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T12829","display_name":"Advanced Breast Cancer Therapies","score":0.8065999746322632,"subfield":{"id":"https://openalex.org/subfields/2740","display_name":"Pulmonary and Respiratory Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10804","display_name":"Health Systems, Economic Evaluations, Quality of Life","score":0.18870000541210175,"subfield":{"id":"https://openalex.org/subfields/2002","display_name":"Economics and Econometrics"},"field":{"id":"https://openalex.org/fields/20","display_name":"Economics, Econometrics and Finance"},"domain":{"id":"https://openalex.org/domains/2","display_name":"Social Sciences"}},{"id":"https://openalex.org/T12708","display_name":"Economic and Financial Impacts of Cancer","score":0.000699999975040555,"subfield":{"id":"https://openalex.org/subfields/2002","display_name":"Economics and Econometrics"},"field":{"id":"https://openalex.org/fields/20","display_name":"Economics, Econometrics and Finance"},"domain":{"id":"https://openalex.org/domains/2","display_name":"Social Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/cdk4-6-inhibitors","display_name":"CDK4/6 inhibitors","score":0.9950000047683716},{"id":"https://openalex.org/keywords/hr-her2-metastatic-breast-cancer","display_name":"HR+/HER2- metastatic breast cancer","score":0.972000002861023},{"id":"https://openalex.org/keywords/cost-effectiveness","display_name":"cost-effectiveness","score":0.8159999847412109},{"id":"https://openalex.org/keywords/first-line-treatment","display_name":"first-line therapy","score":0.7519999742507935},{"id":"https://openalex.org/keywords/letrozole","display_name":"letrozole","score":0.9179999828338623},{"id":"https://openalex.org/keywords/abemaciclib","display_name":"abemaciclib","score":0.8330000042915344},{"id":"https://openalex.org/keywords/ribociclib","display_name":"ribociclib","score":0.9639999866485596},{"id":"https://openalex.org/keywords/palbociclib","display_name":"palbociclib","score":1.0},{"id":"https://openalex.org/keywords/endocrine-therapy","display_name":"endocrine therapy","score":0.800000011920929},{"id":"https://openalex.org/keywords/postmenopausal-women","display_name":"postmenopausal women","score":0.8450000286102295},{"id":"https://openalex.org/keywords/quality-adjusted-life-years","display_name":"quality-adjusted life years","score":0.9390000104904175},{"id":"https://openalex.org/keywords/neutropenia","display_name":"neutropenia","score":0.7049999833106995},{"id":"https://openalex.org/keywords/third-party-payer-perspective","display_name":"third-party payer perspective","score":0.5950000286102295},{"id":"https://openalex.org/keywords/markov-decision-process","display_name":"Markov decision process","score":0.6570000052452087},{"id":"https://openalex.org/keywords/united-states-health-care-costs","display_name":"United States health care costs","score":0.46399998664855957}],"concepts":[{"id":"https://openalex.org/C2778812593","wikidata":"https://www.wikidata.org/wiki/Q194974","display_name":"Letrozole","level":5,"score":0.928971529006958},{"id":"https://openalex.org/C2779744173","wikidata":"https://www.wikidata.org/wiki/Q15269707","display_name":"Palbociclib","level":5,"score":0.886452853679657},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.7747828364372253},{"id":"https://openalex.org/C530470458","wikidata":"https://www.wikidata.org/wiki/Q128581","display_name":"Breast cancer","level":3,"score":0.6748566627502441},{"id":"https://openalex.org/C143998085","wikidata":"https://www.wikidata.org/wiki/Q162555","display_name":"Oncology","level":1,"score":0.6127806901931763},{"id":"https://openalex.org/C2775930923","wikidata":"https://www.wikidata.org/wiki/Q12859063","display_name":"Metastatic breast cancer","level":4,"score":0.6031144261360168},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.5595420002937317},{"id":"https://openalex.org/C3019080777","wikidata":"https://www.wikidata.org/wiki/Q1754768","display_name":"Cost effectiveness","level":2,"score":0.534789502620697},{"id":"https://openalex.org/C64332521","wikidata":"https://www.wikidata.org/wiki/Q614165","display_name":"Quality-adjusted life year","level":3,"score":0.43995505571365356},{"id":"https://openalex.org/C29456083","wikidata":"https://www.wikidata.org/wiki/Q1221899","display_name":"Gynecology","level":1,"score":0.34103062748908997},{"id":"https://openalex.org/C121608353","wikidata":"https://www.wikidata.org/wiki/Q12078","display_name":"Cancer","level":2,"score":0.3371521830558777},{"id":"https://openalex.org/C2776166826","wikidata":"https://www.wikidata.org/wiki/Q415287","display_name":"Aromatase","level":4,"score":0.26809102296829224},{"id":"https://openalex.org/C112930515","wikidata":"https://www.wikidata.org/wiki/Q4389547","display_name":"Risk analysis (engineering)","level":1,"score":0.0}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.1158/1538-7445.am2021-891","doi":"https://doi.org/10.1158/1538-7445.am2021-891","is_oa":false,"landing_page_url":"https://doi.org/10.1158/1538-7445.am2021-891","pdf_url":null,"source":{"id":"https://openalex.org/S168522863","display_name":"Cancer Research","issn_l":"0008-5472","issn":["0008-5472","1538-7445"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320273","host_organization_name":"American Association for Cancer Research","host_organization_lineage":["https://openalex.org/P4310320273"],"host_organization_lineage_names":["American Association for Cancer Research"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Cancer Research","raw_type":"journal-article"}],"best_oa_location":null,"sustainable_development_goals":[{"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being","score":0.9537000060081482}],"study_designs":[],"awards":[],"funders":[],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W4324311233","https://openalex.org/W4400963073","https://openalex.org/W4402700868","https://openalex.org/W4322771468","https://openalex.org/W4412756572","https://openalex.org/W4381053902","https://openalex.org/W4387808273","https://openalex.org/W2809230902","https://openalex.org/W4399324799","https://openalex.org/W4409404072"],"abstract_inverted_index":{"Abstract":[0],"BACKGROUND:":[1],"Cyclin-dependent":[2],"kinase":[3],"4":[4],"and":[5,120,154,159,167,173,199,231,239,254,330,341,439],"6":[6],"(CDK4/6)":[7],"inhibitors":[8,28,63,365,406],"are":[9],"changing":[10],"the":[11,14,57,74,92,99,136,165,207,210,215,223,244,305,315,336,349,352,363,370,386,408,420,427],"management":[12],"of":[13,26,60,76,95,139,209,246,290,298,304,328,333,362,369,373,389,404,411,426],"patients":[15],"with":[16,269,348],"hormone":[17],"receptor-positive/HER2-negative":[18],"metastatic":[19,413],"breast":[20,414],"cancer":[21,415],"(HR+/HER2-":[22],"MBC).":[23],"The":[24,133,318],"addition":[25],"CDK4/6":[27,62,364,374,405],"to":[29,55,64,72,205,281,309,322,335,380],"endocrine":[30,36],"therapy":[31,37],"is":[32,45],"more":[33,47],"efficacious":[34],"than":[35],"alone":[38],"for":[39,228,278,339,385,430],"HR+/HER2-":[40,390,412],"MBC":[41,97],"patients,":[42],"but":[43],"it":[44],"also":[46],"expensive.":[48],"This":[49],"cost-effectiveness":[50,75,195],"analysis":[51],"study":[52,358],"was":[53,182,249,267,307,314,320,378],"designed":[54],"evaluate":[56,73,206],"economic":[58],"value":[59],"adding":[61],"letrozole,":[65],"an":[66,382],"aromatase":[67],"inhibitor.":[68],"OBJECTIVE:":[69],"We":[70,103],"aimed":[71],"abemaciclib":[77],"plus":[78,82,86,233,252,256,263,271,285],"letrozole":[79,83,87,89,179,234,247,253,257,272,282,286,376],"or":[80,84,142],"ribociclib":[81],"palbociclib":[85],"versus":[88],"monotherapy":[90,248,313,377],"in":[91,98,214,288,407,416,419],"first-line":[93,387,409],"treatment":[94,388,410],"HR+/HER2\u2212":[96],"United":[100,421],"States.":[101],"METHODS:":[102],"constructed":[104],"a":[105,124,129,140,150],"Markov-based":[106],"decision-analytic":[107],"model":[108,116,134,216,319],"using":[109],"TreeAge":[110],"Software":[111],"LLC,":[112],"Cambridge,":[113],"MA.":[114],"Our":[115,357],"simulates":[117],"lifetime":[118,126],"costs":[119,227],"health":[121,225],"outcomes":[122],"over":[123],"40-year":[125],"horizon":[127],"from":[128,164,184,351],"third-party":[130],"payer":[131],"perspective.":[132],"incorporated":[135],"clinical":[137,158,168],"course":[138],"progression-free":[141],"stable":[143,334],"disease,":[144,146],"progressed":[145,337],"death,":[147],"Neutropenia":[148],"as":[149,326],"major":[151],"adverse":[152],"effect,":[153],"cancer-specific":[155],"mortality.":[156],"All":[157],"utilities":[160],"data":[161,181],"were":[162,187,203,235,258,346,366],"derived":[163,183],"literature":[166],"trials,":[169],"including":[170],"PALOMA-2,":[171],"MONALEESA-2,":[172],"MONARCH-3.":[174,185],"For":[175],"consistent":[176,347],"comparison,":[177],"only":[178],"specific":[180],"Outcomes":[186],"measured":[188],"by":[189,261],"costs,":[190],"quality-adjusted":[191],"life-years":[192],"(QALYs),":[193],"incremental":[194],"ratios":[196],"(ICERs).":[197],"Deterministic":[198],"probabilistic":[200],"sensitivity":[201],"analyses":[202],"performed":[204],"robustness":[208],"results":[211,345],"against":[212],"uncertainties":[213],"parameters.":[217],"RESULTS:":[218],"In":[219],"our":[220],"base":[221],"case,":[222],"total":[224],"care":[226],"Palbociclib,":[229],"Ribociclib,":[230],"Abemaciclib":[232,262,270,284,340],"$680,596,":[236],"$":[237,240,291],"676,292,":[238],"635,606,":[241],"respectively":[242],"while":[243],"cost":[245,327,372],"$162,378.":[250],"Palbociclib":[251],"Ribociclib":[255],"dominated":[259],"strategies":[260,306],"letrozole.":[264,342],"Higher":[265],"QALYs":[266,274,277],"associated":[268],"(6.91":[273],"vs":[275],"5.83":[276],"letrozole).":[279],"Compared":[280],"monotherapy,":[283],"resulted":[287],"ICER":[289],"436,855":[292],"per":[293,300],"QALY.":[294],"At":[295],"willingness-to-pay":[296],"thresholds":[297],"$100,000":[299],"QALY":[301],"gained,":[302],"none":[303,361],"found":[308,359,379],"be":[310,381],"cost-effective.":[311,367],"Letrozole":[312],"optimal":[316,383],"choice.":[317],"sensitive":[321],"certain":[323],"parameters":[324],"such":[325],"Abemaciclib,":[329],"transition":[331],"probability":[332],"state":[338],"Base":[343],"case":[344],"findings":[350],"Monte":[353],"Carlo":[354],"simulation.":[355],"CONCLUSIONS:":[356],"that":[360],"Because":[368],"current":[371],"inhibitors,":[375],"choice":[384],"MBC.":[391],"Citation":[392],"Format:":[393],"Prajakta":[394],"P.":[395],"Masurkar,":[396],"Haluk":[397],"Damgacioglu,":[398],"Ashish":[399],"Deshmukh,":[400],"Meghana":[401],"Trivedi.":[402],"Cost-effectiveness":[403],"postmenopausal":[417],"women":[418],"States":[422],"[abstract].":[423],"In:":[424],"Proceedings":[425],"American":[428],"Association":[429],"Cancer":[431,445],"Research":[432],"Annual":[433],"Meeting":[434],"2021;":[435],"2021":[436],"Apr":[437],"10-15":[438],"May":[440],"17-21.":[441],"Philadelphia":[442],"(PA):":[443],"AACR;":[444],"Res":[446],"2021;81(13_Suppl):Abstract":[447],"nr":[448],"891.":[449]},"counts_by_year":[{"year":2024,"cited_by_count":1},{"year":2023,"cited_by_count":1},{"year":2021,"cited_by_count":1}],"updated_date":"2026-10-02T10:15:12.560889","created_date":"2021-07-19T00:00:00"}